Learning Objectives

Upon completion of this activity participants should be able to:

  • Describe the current evidence supporting semaglutide in the treatment of Type 2 Diabetes.

  • Apply current ADA recommendations for cardio-renal-metabolic risk reduction.

  • Identify patients most likely to benefit from GLP-1 receptor agonist therapy.

  • Safely initiate and titrate semaglutide in clinical practice.

  • Recognize contraindications and precautions associated with semaglutide therapy.

  • Counsel patients regarding expected adverse effects and strategies to improve adherence.

Course curriculum

    1. Beyond HbA1c: “Contemporary Cardio-Renal-Metabolic Management of Type 2 Diabetes Mellitus”

    2. CME MCQs

About this course

  • Free
  • 2 lessons
  • 2.5 hours of video content
  • 2.5 CME Credits